“FORMULATION AND EVALUATION OF MEFENAMIC ACID AND RABEPRAZOLE SUSTAINED RELEASE TABLET”
1
Author(s):
DINESH S. WANJARI
Vol - 5, Issue- 6 ,
Page(s) : 147 - 154
(2014 )
DOI : https://doi.org/10.32804/IRJMST
Abstract
INTRODUCTION
The oral route is the most common route of drug administration, because of its advantages in terms of convenient administration. Pharmaceutical products designed are mostly immediate release type, designed for immediate release of drug for rapid absorption. Sustained release formulation is design to achieve steady state blood level and non toxic for extended period of time.
Rationale for Selection of Drug :-
The basic goal of this therapy is to maintained steady state blood level for Extended period of time better therapeutic efficiency less side effect reduced dosage regimen.
Mefenamic acid is Non Steroidal Anti- Inflamatory Drug use as Analgesic particularly for Menstrual pain that happen on or before of Menstruation and as analgesic for joint pain.
Rabeprazole is Proton Pump Inhibitor which inhibit the H+/K+ -ATPase pump present on gastric parietal cell of stomach the most potent anti secretory compound for Treatment of Acidity.
Sustained release preparations provide an immediate dose required for the normal therapeutic response, followed by the gradual release of drug in amounts sufficient to maintain the therapeutic response for a specific extended period of time.
- Amaravati V.,Firoz S.,(2012),“Formulation and evaluation of Mefenamic acid
- Tablet by using Modified starch” AJPST, Vol 2 Page No 46-53
- Aulton M.E., (2002), “Pharmceutics” The Science of dosage form design, Churchill Livingstone, 2nd edition. Page No 414-418.
- Banerjee T., Muruganantham V., Venkateswarlu B. S., (2011), “Formulation and evaluation of mucoadhesive tablets of NSAIDS combination with proton pump inhibitor” Department of Pharmaceutics Vinayaka Mission College of Pharmacy Tamil Nadu.
- Bharathi, A., Kalyana, N., (2011), “Formulation and In Vitro Evaluation of Diclofenac Sodium Sustained Release Matrix Tablets using melt Granulation Technique” IJPBS, Vol. 2. Page No 788-808.
- Bramanker M.,Jaiswal., Sunil B.,(1995),“Biopharmaceutics and Pharmacokinetics”, 1st edition. Page No-347-351.
- Clarke's Analysis of Drugs and Poisons.,(2005) , Pharmaceutical Press 3’rd edition
- Dabbagh M.A., Beitmashal L.,(2007),“Sustained release formulation and In vitro evaluation of Ibuprofen-HPMC matrix tablet”, Landishapur JNPP, Volume 01,Page No 1-7
- Dhillon S., (2011), “Naproxen and Esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers”, Adis a Wolters Kliwer business Auckland New Zealand.
- Dusane A.R., Gaikwad P.D., Bankar V.H., Pawar S.P.,(2011), “A Review on : Sustained Release system”, IJRAP, Vol 2 Page No 1701-1708
- George, M.G.,Robinson, J.R.,(1990) “Modern Pharmaceutics, ( Banker, G.S., Rhodes H. Eds.), Forth edition., , Marcel Dekker Inc” New York, Page No 151-152
- Gupta M.M., Bhavesh P.,2013, “ Sustained release dosage form: Comcept and formulation”, IJPRBS, Page No-104-112
- http://en.wikipedia.org/wiki/Menstrual disorder., (Date:25/06/2012)
- http://en.wikipedia.org/wiki/Rabeprazole., (Date:26/06/2012)
- http://en.wikipedia.org/wiki/Mefenamic acid., (Date:25/06/2012)
|